Literature DB >> 26550271

Expression of FOXC2 in renal cell carcinoma and its relationship to clinical pathological features.

Ting-Yi Sun1, Hong-Jian Xie1, Zhen Li1, Ling-Fei Kong1.   

Abstract

OBJECTIVE: This study aimed to investigate expression level of FOXC2 and its relationship to clinical pathological features of renal cell carcinoma (RCC).
METHODS: The expression levels of FOXC2 in RCC tissues and normal renal tissues (62 samples, respectively) were detected by immunohistochemistry and PCR Array. Statistics analyses were done with SPSS to compare the differences between RCC tissues and normal renal tissue, and to explore the relationship between the expression level of FOXC2 and the clinical pathological features of RCC.
RESULTS: Expression level of FOXC2 in RCC tissues was significantly higher than in normal renal tissues, and other related cancer genes also highly expressed in RCC tissues. FOXC2 expression was positively associated with clinical stage and pathological grade (P < 0.05), but not significantly related to the gender and age (P > 0.05).
CONCLUSION: The expression of FOXC2 in renal cell carcinoma was significantly higher than that in normal renal tissues. It is suggested that FOXC2 might play a crucial role in the occurrence and development of RCC and could be an important prognostic indicator for clinical therapy.

Entities:  

Keywords:  FOXC2; PCR array; Renal cell carcinoma; immunohistochemisty

Year:  2015        PMID: 26550271      PMCID: PMC4612956     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  12 in total

Review 1.  The changing natural history of renal cell carcinoma.

Authors:  A J Pantuck; A Zisman; A S Belldegrun
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

2.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

Authors:  Barbara Sennino; Beverly L Falcón; Dilara McCauley; Tom Le; Thomas McCauley; Jeffrey C Kurz; Amy Haskell; David M Epstein; Donald M McDonald
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  The role of EMT in renal fibrosis.

Authors:  Rosemarie M Carew; Bo Wang; Phillip Kantharidis
Journal:  Cell Tissue Res       Date:  2011-08-16       Impact factor: 5.249

4.  FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma.

Authors:  Naohiro Nishida; Koshi Mimori; Takehiko Yokobori; Tomoya Sudo; Fumiaki Tanaka; Kohei Shibata; Hideshi Ishii; Yuichiro Doki; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2010-08-28       Impact factor: 5.344

Review 5.  Foxc2 transcription factor: a newly described regulator of angiogenesis.

Authors:  Tsutomu Kume
Journal:  Trends Cardiovasc Med       Date:  2008-08       Impact factor: 6.677

6.  FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

Authors:  Brett G Hollier; Agata A Tinnirello; Steven J Werden; Kurt W Evans; Joseph H Taube; Tapasree Roy Sarkar; Nathalie Sphyris; Maryam Shariati; Sreedevi V Kumar; Venkata L Battula; Jason I Herschkowitz; Rudy Guerra; Jeffrey T Chang; Naoyuki Miura; Jeffrey M Rosen; Sendurai A Mani
Journal:  Cancer Res       Date:  2013-02-01       Impact factor: 12.701

Review 7.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

8.  Renal cell cancer stage migration: analysis of the National Cancer Data Base.

Authors:  Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

9.  Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts.

Authors:  Elisabeth M Zeisberg; Scott Potenta; Liang Xie; Michael Zeisberg; Raghu Kalluri
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

10.  Mesenchymal-epithelial transition in epithelial response to injury: the role of Foxc2.

Authors:  C Hader; A Marlier; L Cantley
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more
  2 in total

1.  Meta-analysis of the likelihood of FOXC2 expression in early- and late-stage tumors.

Authors:  Tsutomu Kume; Tarek Shackour
Journal:  Oncotarget       Date:  2018-09-07

2.  Expression of combined interference of slug and FoxC2 in endometrial carcinoma and its clinicopathological relationship.

Authors:  Qing Zhu; Ligao Wu; Mingyang Tang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.